Product How it works Pricing Blog FAQ About Contact
BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (NASDAQ: BCRX) net income

BioCryst Pharmaceuticals reported a net profit of $263.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $88.9m. Its net margin was 30.2%. Earnings per share were $1.26.

Fiscal 2025 is the highest of the 10 fiscal years on record for BioCryst Pharmaceuticals. It reported a loss in 9 of those 10 years.

Net income, in millions of US dollars-55.12016-65.82017-101.32018-108.92019-182.82020-184.12021-247.12022-226.52023-88.92024263.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025$263.9m—30.2%$1.26
2024−$88.9m—−19.7%−$0.43
2023−$226.5m—−68.4%−$1.18
2022−$247.1m—−91.2%−$1.33
2021−$184.1m—−117.1%−$1.03
2020−$182.8m—−1,026.4%−$1.09
2019−$108.9m—−223.0%—
2018−$101.3m—−490.3%—
2017−$65.8m—−261.2%—
2016−$55.1m—−209.3%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

BioCryst Pharmaceuticals net income compared with its sector

By net income for its latest fiscal year, BioCryst Pharmaceuticals ranks 79th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of BioCryst Pharmaceuticals, 30.2%.

RankCompanyNet incomeNet margin
77thInnoviva$271.2m65.9%
78thChemed$265.2m10.5%
79thBioCryst Pharmaceuticals$263.9m30.2%
80thInsulet$247.1m9.1%
81stAlkermes$241.7m16.4%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of BioCryst Pharmaceuticals

How much did BioCryst Pharmaceuticals earn in fiscal 2025?
BioCryst Pharmaceuticals reported a net profit of $263.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $88.9m.
What are the earnings per share of BioCryst Pharmaceuticals?
They were $1.26 in fiscal 2025, compared with −$0.43 in fiscal 2024.
What is the net margin of BioCryst Pharmaceuticals?
In fiscal 2025 its net profit was 30.2% of its revenue.
What was the most profitable year for BioCryst Pharmaceuticals?
Of its last 10 fiscal years, fiscal 2025, with $263.9m.
Where does BioCryst Pharmaceuticals rank in its sector by net income?
It ranks 79th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for BioCryst Pharmaceuticals come from?
From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on BioCryst Pharmaceuticals: the BioCryst Pharmaceuticals page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.